Related Experiment Video
Updated: Jun 4, 2026
10:24
Regenerative Therapy by Suprachoroidal Cell Autograft in Dry Age-related Macular Degeneration: Preliminary In Vivo Report
Published on: February 12, 2018
Finasteride for chronic central serous chorioretinopathy.
Farzin Forooghian1, Annal D Meleth, Catherine Cukras
1Division of Epidemiology and Clinical Applications, National Eye Institute, National Institutes of Health, Bethesda, Maryland, USA.
Retina (Philadelphia, Pa.)
|January 29, 2011
Summary
Finasteride shows potential for treating chronic central serous chorioretinopathy by reducing dihydrotestosterone. Further clinical trials are necessary to confirm its efficacy and safety in patients.
Area of Science:
- Ophthalmology
- Endocrinology
Background:
- Chronic central serous chorioretinopathy (cCSC) is a condition affecting vision.
- Dihydrotestosterone (DHT) plays a role in cCSC pathogenesis.
Purpose of the Study:
- To assess the safety and efficacy of finasteride, a DHT synthesis inhibitor, for treating cCSC.
- To evaluate finasteride's impact on visual acuity and retinal structure in cCSC patients.
Main Methods:
- Pilot study involving five patients with cCSC.
- Daily finasteride (5 mg) for 3 months, followed by a 3-month observation period.
- Measurements included visual acuity, optical coherence tomography (OCT) for macular thickness and subretinal fluid, and hormone levels (DHT, testosterone, cortisol).
Main Results:
- No significant change in best-corrected visual acuity observed.
- Macular thickness and subretinal fluid initially decreased but increased after finasteride cessation in most patients.
- One patient achieved normalized OCT parameters with finasteride, which remained stable post-treatment.
Conclusions:
- Finasteride may offer a new therapeutic approach for cCSC.
- Larger, controlled trials are required to validate finasteride's efficacy in cCSC treatment.
Related Concept Videos
01:27Open Angle Glaucoma: Treatment
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
Drugs such as carbonic anhydrase inhibitors, α2- and...
01:28Angle Closure Glaucoma: Treatment
Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...
01:27Diabetic Retinopathy
DefinitionDiabetic retinopathy is a microvascular complication of diabetes affecting the retinal blood vessels.Risk FactorsDiabetic retinopathy is present in almost all individuals with type 1 diabetes and more than 60% of those with type 2 diabetes after two decades of disease.The risk increases with poor glycemic control, hypertension, dyslipidemia, smoking, pregnancy, and puberty.Although cataracts and glaucoma are also more frequent in people with diabetes, retinopathy remains the leading...
01:25Glaucoma: Overview
Glaucoma is an eye condition characterized by increased intraocular pressure that damages the retina and optic nerve, leading to irreversible blindness if left untreated. The human eye has various components, including the cornea, iris, pupil, lens, and optic nerve. Aqueous humor is secreted by the epithelium of the ciliary body in the posterior chamber and flows through the trabecular meshwork and canal of Schlemm, maintaining normal intraocular pressure. The trabecular meshwork and the canal...